Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

SUBODH K BHUCHAR

Allopathic & Osteopathic Physicians Family Medicine

NPI
1629082417
CMS profile
210092
Location
SUGAR LAND, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$1,008.09

60 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,008.09 60

By paying entity

PY2023 · entire year · sorted by reported total

Page 1 of 2; records 1–50 of 60 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

SUBODH K BHUCHAR

NPI 1629082417 · CMS profile ID 210092

Allopathic & Osteopathic Physicians / Family Medicine

SUGAR LAND, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 2; records 1–50 of 60 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1629082417?year=2023&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
SUBODH K BHUCHAR, NPI 1629082417, CMS profile ID 210092. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 2; records 1–50 of 60 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1629082417?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). SUBODH K BHUCHAR, NPI 1629082417, CMS profile ID 210092. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 2; records 1–50 of 60 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1629082417?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
SUBODH K BHUCHAR, NPI 1629082417, CMS profile ID 210092, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 2; records 1–50 of 60 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1629082417?year=2023&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

60 matching records · $1,008.09 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 60 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–50 of 60.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Novo Nordisk Inc $3.6112/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000470157 CMS
Optinose US, Inc. $13.1011/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1035222885 CMS
Amgen Inc. $19.1911/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020684071 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $17.1010/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057364885 CMS
Novo Nordisk Inc $4.4310/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000470167 CMS
AstraZeneca Pharmaceuticals LP $19.8310/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1024987497 CMS
PFIZER INC. $14.3610/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049549743 CMS
Novo Nordisk Inc $12.9910/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000470219 CMS
Novo Nordisk Inc $6.1410/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000470205 CMS
GlaxoSmithKline, LLC. $20.4110/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1002088496 CMS
PFIZER INC. $18.4309/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050653859 CMS
Novo Nordisk Inc $18.6809/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000470245 CMS
AstraZeneca Pharmaceuticals LP $25.0609/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025038989 CMS
Amgen Inc. $14.4009/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020684069 CMS
Cranial Technologies, Inc $14.5709/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1035790467 CMS
Novo Nordisk Inc $7.3109/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000470213 CMS
Lilly USA, LLC $16.6009/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032359037 CMS
Bayer Healthcare Pharmaceuticals Inc. $27.2209/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000186677 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $18.7808/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996943769 CMS
Novo Nordisk Inc $5.6208/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000470181 CMS
AstraZeneca Pharmaceuticals LP $16.2208/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025015735 CMS
Mylan Specialty L.P. $20.9208/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1039116423 CMS
Novo Nordisk Inc $3.5908/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000470149 CMS
Bayer Healthcare Pharmaceuticals Inc. $19.7808/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000136059 CMS
GlaxoSmithKline, LLC. $22.0908/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1002088405 CMS
Lilly USA, LLC $14.7208/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032191760 CMS
Novo Nordisk Inc $15.8707/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000470235 CMS
Astellas Pharma US Inc $19.1407/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1034295195 CMS
Lilly USA, LLC $24.0007/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032314581 CMS
Bayer Healthcare Pharmaceuticals Inc. $22.2207/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000161077 CMS
GlaxoSmithKline, LLC. $13.8307/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1002090815 CMS
Bayer Healthcare Pharmaceuticals Inc. $7.8806/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000037825 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $22.9106/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996943773 CMS
Lilly USA, LLC $20.5706/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032359027 CMS
AstraZeneca Pharmaceuticals LP $15.2206/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025066305 CMS
Bayer Healthcare Pharmaceuticals Inc. $17.3206/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000105189 CMS
Amgen Inc. $17.1705/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020684067 CMS
Lilly USA, LLC $22.5005/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032239639 CMS
Novo Nordisk Inc $4.6805/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000470173 CMS
GlaxoSmithKline, LLC. $12.9005/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1002088461 CMS
Novo Nordisk Inc $23.0705/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000470261 CMS
Novo Nordisk Inc $5.8704/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000470189 CMS
Bayer Healthcare Pharmaceuticals Inc. $20.6804/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000145081 CMS
Novo Nordisk Inc $6.0204/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000470197 CMS
GlaxoSmithKline, LLC. $22.5304/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1002090920 CMS
Novo Nordisk Inc $14.5004/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000470229 CMS
Lilly USA, LLC $5.8604/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032145425 CMS
Lilly USA, LLC $12.6404/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032276361 CMS
AstraZeneca Pharmaceuticals LP $16.2303/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025005599 CMS
Merck Sharp & Dohme LLC $28.3203/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048363659 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $687.61 39
PY2020 $1,479.37 97
PY2021 $1,325.84 71
PY2022 $1,349.84 72
PY2023 $1,008.09 60
PY2024 $1,319.47 66
PY2025 $1,138.61 56

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $464,693.66 97
PY2024 Principal investigator $270,025.76 55
PY2023 Principal investigator $54,587.21 12
PY2022 Principal investigator $87,839.75 24
PY2021 Principal investigator $247,965.53 21
PY2020 Principal investigator $26,693.61 27
PY2019 Principal investigator $57,601.69 7

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

97 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $1,070.00 12/31/2025 Non-covered Recipient Entity
PIONEER RESEARCH SOLUTIONS INC
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Single-attack Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Oral Ubrogepant in the Acute Treatment of Migraine With or Without Aura in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202533587
Principal investigator 1 GlaxoSmithKline, LLC. $9,500.00 12/19/2025 Non-covered Recipient Entity
PIONEER RESEARCH SOLUTIONS INC
A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVEST No dispute reported 06/30/2026 1192120775
Principal investigator 1 Ardelyx, Inc. $12,754.00 12/16/2025 Non-covered Recipient Entity
PIONEER RESEARCH SOLUTIONS INC
Phase II Dose ranging safety and efficacy studying IBS-C patients 6-12 years old No dispute reported 06/30/2026 1247838896
Principal investigator 1 Ardelyx, Inc. $4,920.00 12/16/2025 Non-covered Recipient Entity
PIONEER RESEARCH SOLUTIONS INC
Phase II Dose ranging safety and efficacy studying IBS-C patients 6-12 years old No dispute reported 06/30/2026 1247838899
Principal investigator 1 Ardelyx, Inc. $1,282.00 12/16/2025 Non-covered Recipient Entity
PIONEER RESEARCH SOLUTIONS INC
AN OPEN-LABEL LONG-TERM SAFETY STUDY OF TENAPANOR FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C) IN PEDIATRIC PATIENTS 6 TO LESS THAN 18 YEARS OLD No dispute reported 06/30/2026 1247838904
Principal investigator 1 Ardelyx, Inc. $507.00 12/16/2025 Non-covered Recipient Entity
PIONEER RESEARCH SOLUTIONS INC
AN OPEN-LABEL LONG-TERM SAFETY STUDY OF TENAPANOR FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C) IN PEDIATRIC PATIENTS 6 TO LESS THAN 18 YEARS OLD No dispute reported 06/30/2026 1247838908
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,247.30 12/11/2025 Non-covered Recipient Entity
PIONEER RESEARCH SOLUTIONS INC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244049767
Principal investigator 1 ABBVIE INC. $270.00 12/04/2025 Non-covered Recipient Entity
PIONEER RESEARCH SOLUTIONS INC
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202526722
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $479.82 11/13/2025 Non-covered Recipient Entity
PIONEER RESEARCH SOLUTIONS INC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244049769
Principal investigator 1 ABBVIE INC. $270.00 11/05/2025 Non-covered Recipient Entity
PIONEER RESEARCH SOLUTIONS INC
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202521573
Principal investigator 1 Ardelyx, Inc. $11,370.00 11/04/2025 Non-covered Recipient Entity
PIONEER RESEARCH SOLUTIONS INC
Phase II Dose ranging safety and efficacy studying IBS-C patients 6-12 years old No dispute reported 06/30/2026 1247838795
Principal investigator 1 Ardelyx, Inc. $3,813.00 11/04/2025 Non-covered Recipient Entity
PIONEER RESEARCH SOLUTIONS INC
AN OPEN-LABEL LONG-TERM SAFETY STUDY OF TENAPANOR FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C) IN PEDIATRIC PATIENTS 6 TO LESS THAN 18 YEARS OLD No dispute reported 06/30/2026 1247838799
Principal investigator 1 Ardelyx, Inc. $507.00 11/04/2025 Non-covered Recipient Entity
PIONEER RESEARCH SOLUTIONS INC
AN OPEN-LABEL LONG-TERM SAFETY STUDY OF TENAPANOR FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C) IN PEDIATRIC PATIENTS 6 TO LESS THAN 18 YEARS OLD No dispute reported 06/30/2026 1247838801
Principal investigator 1 Ardelyx, Inc. $80.40 11/04/2025 Non-covered Recipient Entity
PIONEER RESEARCH SOLUTIONS INC
AN OPEN-LABEL LONG-TERM SAFETY STUDY OF TENAPANOR FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C) IN PEDIATRIC PATIENTS 6 TO LESS THAN 18 YEARS OLD No dispute reported 06/30/2026 1247838804
Principal investigator 1 GlaxoSmithKline, LLC. $2,050.00 11/04/2025 Non-covered Recipient Entity
PIONEER RESEARCH SOLUTIONS INC
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192120749
Principal investigator 1 Ardelyx, Inc. $4,400.00 10/29/2025 Non-covered Recipient Entity
PIONEER RESEARCH SOLUTIONS INC
TEN 01-304 -SAFETY AND EFFICACY PHASE 03 IN 12-18 YEAR OLDS No dispute reported 06/30/2026 1247838713
Principal investigator 1 Ardelyx, Inc. $3,000.00 10/29/2025 Non-covered Recipient Entity
PIONEER RESEARCH SOLUTIONS INC
TEN 01-304 -SAFETY AND EFFICACY PHASE 03 IN 12-18 YEAR OLDS No dispute reported 06/30/2026 1247838717
Principal investigator 1 Ardelyx, Inc. $1,500.00 10/29/2025 Non-covered Recipient Entity
PIONEER RESEARCH SOLUTIONS INC
TEN 01-304 -SAFETY AND EFFICACY PHASE 03 IN 12-18 YEAR OLDS No dispute reported 06/30/2026 1247838722
Principal investigator 1 Ardelyx, Inc. $517.00 10/29/2025 Non-covered Recipient Entity
PIONEER RESEARCH SOLUTIONS INC
Phase II Dose ranging safety and efficacy studying IBS-C patients 6-12 years old No dispute reported 06/30/2026 1247838724
Principal investigator 1 Ardelyx, Inc. $500.00 10/29/2025 Non-covered Recipient Entity
PIONEER RESEARCH SOLUTIONS INC
Phase II Dose ranging safety and efficacy studying IBS-C patients 6-12 years old No dispute reported 06/30/2026 1247838729
Principal investigator 1 Ardelyx, Inc. $40.20 10/20/2025 Non-covered Recipient Entity
PIONEER RESEARCH SOLUTIONS INC
AN OPEN-LABEL LONG-TERM SAFETY STUDY OF TENAPANOR FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C) IN PEDIATRIC PATIENTS 6 TO LESS THAN 18 YEARS OLD No dispute reported 06/30/2026 1247838702
Principal investigator 1 Ardelyx, Inc. $2,553.00 10/14/2025 Non-covered Recipient Entity
PIONEER RESEARCH SOLUTIONS INC
AN OPEN-LABEL LONG-TERM SAFETY STUDY OF TENAPANOR FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C) IN PEDIATRIC PATIENTS 6 TO LESS THAN 18 YEARS OLD No dispute reported 06/30/2026 1247838668
Principal investigator 1 GlaxoSmithKline, LLC. $70.20 10/14/2025 Non-covered Recipient Entity
PIONEER RESEARCH SOLUTIONS INC
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192120764
Principal investigator 1 GlaxoSmithKline, LLC. $63.45 10/14/2025 Non-covered Recipient Entity
PIONEER RESEARCH SOLUTIONS INC
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192120770
Principal investigator 1 Ardelyx, Inc. $681.00 10/08/2025 Non-covered Recipient Entity
PIONEER RESEARCH SOLUTIONS INC
Phase II Dose ranging safety and efficacy studying IBS-C patients 6-12 years old No dispute reported 06/30/2026 1247838658
Principal investigator 1 GlaxoSmithKline, LLC. $12,718.13 09/18/2025 Non-covered Recipient Entity
PIONEER RESEARCH SOLUTIONS INC
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192120192
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $479.82 09/18/2025 Non-covered Recipient Entity
PIONEER RESEARCH SOLUTIONS INC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244049771
Principal investigator 1 Ardelyx, Inc. $5,690.00 09/15/2025 Non-covered Recipient Entity
PIONEER RESEARCH SOLUTIONS INC
Phase II Dose ranging safety and efficacy studying IBS-C patients 6-12 years old No dispute reported 06/30/2026 1247838616
Principal investigator 1 Ardelyx, Inc. $3,824.00 09/15/2025 Non-covered Recipient Entity
PIONEER RESEARCH SOLUTIONS INC
AN OPEN-LABEL LONG-TERM SAFETY STUDY OF TENAPANOR FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C) IN PEDIATRIC PATIENTS 6 TO LESS THAN 18 YEARS OLD No dispute reported 06/30/2026 1247838620
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,103.52 09/11/2025 Non-covered Recipient Entity
PIONEER RESEARCH SOLUTIONS INC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244049773
Principal investigator 1 Ardelyx, Inc. $160.80 08/25/2025 Non-covered Recipient Entity
PIONEER RESEARCH SOLUTIONS INC
AN OPEN-LABEL LONG-TERM SAFETY STUDY OF TENAPANOR FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C) IN PEDIATRIC PATIENTS 6 TO LESS THAN 18 YEARS OLD No dispute reported 06/30/2026 1247838571
Principal investigator 1 GlaxoSmithKline, LLC. $6,538.16 08/20/2025 Non-covered Recipient Entity
PIONEER RESEARCH SOLUTIONS INC
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192120759
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,163.48 08/19/2025 Non-covered Recipient Entity
PIONEER RESEARCH SOLUTIONS INC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244049775
Principal investigator 1 Ardelyx, Inc. $1,950.00 08/18/2025 Non-covered Recipient Entity
PIONEER RESEARCH SOLUTIONS INC
Phase II Dose ranging safety and efficacy studying IBS-C patients 6-12 years old No dispute reported 06/30/2026 1247838546
Principal investigator 1 Ardelyx, Inc. $46.00 08/18/2025 Non-covered Recipient Entity
PIONEER RESEARCH SOLUTIONS INC
TEN 01-304 -SAFETY AND EFFICACY PHASE 03 IN 12-18 YEAR OLDS No dispute reported 06/30/2026 1247838550
Principal investigator 1 Ardelyx, Inc. $4,563.00 08/11/2025 Non-covered Recipient Entity
PIONEER RESEARCH SOLUTIONS INC
Phase II Dose ranging safety and efficacy studying IBS-C patients 6-12 years old No dispute reported 06/30/2026 1247838525
Principal investigator 1 Ardelyx, Inc. $3,933.00 08/11/2025 Non-covered Recipient Entity
PIONEER RESEARCH SOLUTIONS INC
TEN 01-304 -SAFETY AND EFFICACY PHASE 03 IN 12-18 YEAR OLDS No dispute reported 06/30/2026 1247838530
Principal investigator 1 Ardelyx, Inc. $507.00 08/11/2025 Non-covered Recipient Entity
PIONEER RESEARCH SOLUTIONS INC
AN OPEN-LABEL LONG-TERM SAFETY STUDY OF TENAPANOR FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C) IN PEDIATRIC PATIENTS 6 TO LESS THAN 18 YEARS OLD No dispute reported 06/30/2026 1247838534
Principal investigator 1 ABBVIE INC. $11,025.00 08/06/2025 Non-covered Recipient Entity
PIONEER RESEARCH SOLUTIONS INC
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202503557
Principal investigator 1 ABBVIE INC. $11,362.50 08/06/2025 Non-covered Recipient Entity
PIONEER RESEARCH SOLUTIONS INC
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202503559
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $8,186.64 08/06/2025 Non-covered Recipient Entity
PIONEER RESEARCH SOLUTIONS INC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244049777
Principal investigator 1 Ardelyx, Inc. $5,084.00 08/04/2025 Non-covered Recipient Entity
PIONEER RESEARCH SOLUTIONS INC
AN OPEN-LABEL LONG-TERM SAFETY STUDY OF TENAPANOR FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C) IN PEDIATRIC PATIENTS 6 TO LESS THAN 18 YEARS OLD No dispute reported 06/30/2026 1247838519
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $479.82 07/24/2025 Non-covered Recipient Entity
PIONEER RESEARCH SOLUTIONS INC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244049779
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $54,700.80 07/22/2025 Non-covered Recipient Entity
PIONEER RESEARCH SOLUTIONS INC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244049781
Principal investigator 1 GlaxoSmithKline, LLC. $28,677.28 07/21/2025 Non-covered Recipient Entity
PIONEER RESEARCH SOLUTIONS
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192120199
Principal investigator 1 GlaxoSmithKline, LLC. $3,269.08 07/21/2025 Non-covered Recipient Entity
PIONEER RESEARCH SOLUTIONS
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192120743
Principal investigator 1 Ardelyx, Inc. $505.00 07/14/2025 Non-covered Recipient Entity
PIONEER RESEARCH SOLUTIONS INC
TEN 01-304 -SAFETY AND EFFICACY PHASE 03 IN 12-18 YEAR OLDS No dispute reported 06/30/2026 1247838469
Principal investigator 1 Ardelyx, Inc. $5,487.00 07/07/2025 Non-covered Recipient Entity
PIONEER RESEARCH SOLUTIONS INC
TEN 01-304 -SAFETY AND EFFICACY PHASE 03 IN 12-18 YEAR OLDS No dispute reported 06/30/2026 1247838454
Principal investigator 1 Ardelyx, Inc. $4,465.00 07/07/2025 Non-covered Recipient Entity
PIONEER RESEARCH SOLUTIONS INC
AN OPEN-LABEL LONG-TERM SAFETY STUDY OF TENAPANOR FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C) IN PEDIATRIC PATIENTS 6 TO LESS THAN 18 YEARS OLD No dispute reported 06/30/2026 1247838458
Principal investigator 1 ABBVIE INC. $500.00 07/01/2025 Non-covered Recipient Entity
PIONEER RESEARCH SOLUTIONS INC
Linaclotide Safety and Efficacy in Pediatric Participants 6 to 17 Years of Age With Irritable Bowel Syndrome With Constipation (IBS-C) or Functional Constipation (FC) No dispute reported 06/30/2026 1202493823
Principal investigator 1 Ardelyx, Inc. $2,230.00 07/01/2025 Non-covered Recipient Entity
PIONEER RESEARCH SOLUTIONS INC
Phase II Dose ranging safety and efficacy studying IBS-C patients 6-12 years old No dispute reported 06/30/2026 1247838433
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $3,253.14 06/24/2025 Non-covered Recipient Entity
PIONEER RESEARCH SOLUTIONS INC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244049783
Principal investigator 1 Ardelyx, Inc. $4,047.00 06/16/2025 Non-covered Recipient Entity
PIONEER RESEARCH SOLUTIONS INC
AN OPEN-LABEL LONG-TERM SAFETY STUDY OF TENAPANOR FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C) IN PEDIATRIC PATIENTS 6 TO LESS THAN 18 YEARS OLD No dispute reported 06/30/2026 1247838408
Principal investigator 1 Ardelyx, Inc. $429.00 06/16/2025 Non-covered Recipient Entity
PIONEER RESEARCH SOLUTIONS INC
AN OPEN-LABEL LONG-TERM SAFETY STUDY OF TENAPANOR FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C) IN PEDIATRIC PATIENTS 6 TO LESS THAN 18 YEARS OLD No dispute reported 06/30/2026 1247838413
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $149.70 06/13/2025 Non-covered Recipient Entity
PIONEER RESEARCH SOLUTIONS INC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244049785
Principal investigator 1 GlaxoSmithKline, LLC. $4,000.00 06/06/2025 Non-covered Recipient Entity
PIONEER RESEARCH SOLUTIONS
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192114786
Principal investigator 1 GlaxoSmithKline, LLC. $28,413.99 05/28/2025 Non-covered Recipient Entity
PIONEER RESEARCH SOLUTIONS
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192120781
Principal investigator 1 Ardelyx, Inc. $80.40 05/20/2025 Non-covered Recipient Entity
PIONEER RESEARCH SOLUTIONS INC
AN OPEN-LABEL LONG-TERM SAFETY STUDY OF TENAPANOR FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C) IN PEDIATRIC PATIENTS 6 TO LESS THAN 18 YEARS OLD No dispute reported 06/30/2026 1247838368
Principal investigator 1 GlaxoSmithKline, LLC. $9,000.00 05/16/2025 Non-covered Recipient Entity
PIONEER RESEARCH SOLUTIONS
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192114793
Principal investigator 1 GlaxoSmithKline, LLC. $1,750.00 05/16/2025 Non-covered Recipient Entity
PIONEER RESEARCH SOLUTIONS
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192120738
Principal investigator 1 Ardelyx, Inc. $7,255.00 05/05/2025 Non-covered Recipient Entity
PIONEER RESEARCH SOLUTIONS INC
AN OPEN-LABEL LONG-TERM SAFETY STUDY OF TENAPANOR FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C) IN PEDIATRIC PATIENTS 6 TO LESS THAN 18 YEARS OLD No dispute reported 06/30/2026 1247838310
Principal investigator 1 Ardelyx, Inc. $4,166.00 05/05/2025 Non-covered Recipient Entity
PIONEER RESEARCH SOLUTIONS INC
Phase II Dose ranging safety and efficacy studying IBS-C patients 6-12 years old No dispute reported 06/30/2026 1247838315
Principal investigator 1 Ardelyx, Inc. $1,842.00 05/05/2025 Non-covered Recipient Entity
PIONEER RESEARCH SOLUTIONS INC
TEN 01-304 -SAFETY AND EFFICACY PHASE 03 IN 12-18 YEAR OLDS No dispute reported 06/30/2026 1247838318
Principal investigator 1 Ardelyx, Inc. $1,478.00 05/05/2025 Non-covered Recipient Entity
PIONEER RESEARCH SOLUTIONS INC
TEN 01-304 -SAFETY AND EFFICACY PHASE 03 IN 12-18 YEAR OLDS No dispute reported 06/30/2026 1247838323
Principal investigator 1 AstraZeneca UK Limited $24,818.03 05/05/2025 Non-covered Recipient Entity
PIONEER RESEARCH SOLUTIONS, INC
a phase two a,randomized,double blind,placebo controlled study to assess efficacy and safety of atuliflapon given orally once daily for twelve weeks in adults with moderate to severe uncontrolled asthma No dispute reported 06/30/2026 1185553321
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $3,769.26 04/24/2025 Non-covered Recipient Entity
PIONEER RESEARCH SOLUTIONS INC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244049787
Principal investigator 1 Ardelyx, Inc. $120.60 04/22/2025 Non-covered Recipient Entity
PIONEER RESEARCH SOLUTIONS INC
AN OPEN-LABEL LONG-TERM SAFETY STUDY OF TENAPANOR FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C) IN PEDIATRIC PATIENTS 6 TO LESS THAN 18 YEARS OLD No dispute reported 06/30/2026 1247838273
Principal investigator 1 Ardelyx, Inc. $32.50 04/22/2025 Non-covered Recipient Entity
PIONEER RESEARCH SOLUTIONS INC
TEN 01-304 -SAFETY AND EFFICACY PHASE 03 IN 12-18 YEAR OLDS No dispute reported 06/30/2026 1247838278
Principal investigator 1 Ardelyx, Inc. $32.00 04/22/2025 Non-covered Recipient Entity
PIONEER RESEARCH SOLUTIONS INC
TEN 01-304 -SAFETY AND EFFICACY PHASE 03 IN 12-18 YEAR OLDS No dispute reported 06/30/2026 1247838281
Principal investigator 1 Ardelyx, Inc. $2,269.00 04/15/2025 Non-covered Recipient Entity
PIONEER RESEARCH SOLUTIONS INC
Phase II Dose ranging safety and efficacy studying IBS-C patients 6-12 years old No dispute reported 06/30/2026 1247838256
Principal investigator 1 Ardelyx, Inc. $5,736.00 04/08/2025 Non-covered Recipient Entity
PIONEER RESEARCH SOLUTIONS INC
AN OPEN-LABEL LONG-TERM SAFETY STUDY OF TENAPANOR FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C) IN PEDIATRIC PATIENTS 6 TO LESS THAN 18 YEARS OLD No dispute reported 06/30/2026 1247838224
Principal investigator 1 Ardelyx, Inc. $36.00 04/08/2025 Non-covered Recipient Entity
PIONEER RESEARCH SOLUTIONS INC
TEN 01-304 -SAFETY AND EFFICACY PHASE 03 IN 12-18 YEAR OLDS No dispute reported 06/30/2026 1247838230
Principal investigator 1 Ardelyx, Inc. $46.00 03/24/2025 Non-covered Recipient Entity
PIONEER RESEARCH SOLUTIONS INC
TEN 01-304 -SAFETY AND EFFICACY PHASE 03 IN 12-18 YEAR OLDS No dispute reported 06/30/2026 1247838205
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $3,769.26 03/20/2025 Non-covered Recipient Entity
PIONEER RESEARCH SOLUTIONS INC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244049789
Principal investigator 1 Ardelyx, Inc. $6,250.00 03/19/2025 Non-covered Recipient Entity
PIONEER RESEARCH SOLUTIONS INC
Phase II Dose ranging safety and efficacy studying IBS-C patients 6-12 years old No dispute reported 06/30/2026 1247838195
Principal investigator 1 SANOFI US SERVICES INC. $2,250.00 03/17/2025 Non-covered Recipient Entity
Pioneer Research Solutions Houston Stancliff Road
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab, in Participants With Non-cystic Fibrosis Bronchiectasis No dispute reported 06/30/2026 1226153907
Principal investigator 1 AstraZeneca UK Limited $49,807.57 03/12/2025 Non-covered Recipient Entity
PIONEER RESEARCH SOLUTIONS, INC
a randomized,double blind,multicenter,parallel group,phase IIIb 52 week study evaluating the efficacy and safety of PT027 compared with PT007 administered as needed in participants 12 to under 18 years of age with asthma ACADIA No dispute reported 06/30/2026 1185553319
Principal investigator 1 Ardelyx, Inc. $6,625.00 03/10/2025 Non-covered Recipient Entity
PIONEER RESEARCH SOLUTIONS INC
TEN 01-304 -SAFETY AND EFFICACY PHASE 03 IN 12-18 YEAR OLDS No dispute reported 06/30/2026 1247838176
Principal investigator 1 Ardelyx, Inc. $3,320.00 03/10/2025 Non-covered Recipient Entity
PIONEER RESEARCH SOLUTIONS INC
TEN 01-304 -SAFETY AND EFFICACY PHASE 03 IN 12-18 YEAR OLDS No dispute reported 06/30/2026 1247838180
Principal investigator 1 Ardelyx, Inc. $44.10 03/03/2025 Non-covered Recipient Entity
PIONEER RESEARCH SOLUTIONS INC
TEN 01-304 -SAFETY AND EFFICACY PHASE 03 IN 12-18 YEAR OLDS No dispute reported 06/30/2026 1247838145
Principal investigator 1 Ardelyx, Inc. $19.90 03/03/2025 Non-covered Recipient Entity
PIONEER RESEARCH SOLUTIONS INC
TEN 01-304 -SAFETY AND EFFICACY PHASE 03 IN 12-18 YEAR OLDS No dispute reported 06/30/2026 1247838149
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $5,876.64 02/27/2025 Non-covered Recipient Entity
PIONEER RESEARCH SOLUTIONS INC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244049765
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $204.60 02/25/2025 Non-covered Recipient Entity
PIONEER RESEARCH SOLUTIONS INC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244049793
Principal investigator 1 Ardelyx, Inc. $1,500.00 02/18/2025 Non-covered Recipient Entity
PIONEER RESEARCH SOLUTIONS INC
TEN 01-304 -SAFETY AND EFFICACY PHASE 03 IN 12-18 YEAR OLDS No dispute reported 06/30/2026 1247838129
Principal investigator 1 Ardelyx, Inc. $97.50 02/18/2025 Non-covered Recipient Entity
PIONEER RESEARCH SOLUTIONS INC
TEN 01-304 -SAFETY AND EFFICACY PHASE 03 IN 12-18 YEAR OLDS No dispute reported 06/30/2026 1247838132
Principal investigator 1 Ardelyx, Inc. $9,250.00 02/03/2025 Non-covered Recipient Entity
PIONEER RESEARCH SOLUTIONS INC
TEN 01-304 -SAFETY AND EFFICACY PHASE 03 IN 12-18 YEAR OLDS No dispute reported 06/30/2026 1247838077
Principal investigator 1 Ardelyx, Inc. $6,873.00 02/03/2025 Non-covered Recipient Entity
PIONEER RESEARCH SOLUTIONS INC
AN OPEN-LABEL LONG-TERM SAFETY STUDY OF TENAPANOR FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C) IN PEDIATRIC PATIENTS 6 TO LESS THAN 18 YEARS OLD No dispute reported 06/30/2026 1247838082
Principal investigator 1 Ardelyx, Inc. $210.00 02/03/2025 Non-covered Recipient Entity
PIONEER RESEARCH SOLUTIONS INC
TEN 01-304 -SAFETY AND EFFICACY PHASE 03 IN 12-18 YEAR OLDS No dispute reported 06/30/2026 1247838086
Principal investigator 1 Ardelyx, Inc. $116.00 02/03/2025 Non-covered Recipient Entity
PIONEER RESEARCH SOLUTIONS INC
TEN 01-304 -SAFETY AND EFFICACY PHASE 03 IN 12-18 YEAR OLDS No dispute reported 06/30/2026 1247838090
Principal investigator 1 Ardelyx, Inc. $24.00 02/03/2025 Non-covered Recipient Entity
PIONEER RESEARCH SOLUTIONS INC
TEN 01-304 -SAFETY AND EFFICACY PHASE 03 IN 12-18 YEAR OLDS No dispute reported 06/30/2026 1247838094
Principal investigator 1 Amgen Inc. $9,116.25 01/30/2025 Non-covered Recipient Entity
PIONEER RESEARCH SOLUTIONS INC
A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose Ranging Study to Assess the Efficacy and Safety of Rocatinlimab in Adult Subjects With Moderate-to-severe Asthma No dispute reported 06/30/2026 1246646620
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,044.12 01/16/2025 Non-covered Recipient Entity
PIONEER RESEARCH SOLUTIONS INC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244049791
Principal investigator 1 Ardelyx, Inc. $97.50 01/13/2025 Non-covered Recipient Entity
PIONEER RESEARCH SOLUTIONS INC
TEN 01-304 -SAFETY AND EFFICACY PHASE 03 IN 12-18 YEAR OLDS No dispute reported 06/30/2026 1247838045
Principal investigator 1 Ardelyx, Inc. $40.20 01/13/2025 Non-covered Recipient Entity
PIONEER RESEARCH SOLUTIONS INC
AN OPEN-LABEL LONG-TERM SAFETY STUDY OF TENAPANOR FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C) IN PEDIATRIC PATIENTS 6 TO LESS THAN 18 YEARS OLD No dispute reported 06/30/2026 1247838048
Principal investigator 1 Ardelyx, Inc. $490.90 01/02/2025 Non-covered Recipient Entity
PIONEER RESEARCH SOLUTIONS INC
AN OPEN-LABEL LONG-TERM SAFETY STUDY OF TENAPANOR FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C) IN PEDIATRIC PATIENTS 6 TO LESS THAN 18 YEARS OLD No dispute reported 06/30/2026 1247838008
Principal investigator 1 Ardelyx, Inc. $8,787.00 01/02/2025 Non-covered Recipient Entity
PIONEER RESEARCH SOLUTIONS INC
TEN 01-304 -SAFETY AND EFFICACY PHASE 03 IN 12-18 YEAR OLDS No dispute reported 06/30/2026 1247838030
Principal investigator 1 Ardelyx, Inc. $2,062.10 01/02/2025 Non-covered Recipient Entity
PIONEER RESEARCH SOLUTIONS INC
AN OPEN-LABEL LONG-TERM SAFETY STUDY OF TENAPANOR FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C) IN PEDIATRIC PATIENTS 6 TO LESS THAN 18 YEARS OLD No dispute reported 06/30/2026 1247838034